Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease
NCT05996627
Recruiting
This phase II trial compares the effect of belumosudil to a placebo in treating patients with chronic graft versus host disease. Chronic graft versus host disease remains a major complication of stem cell transplantation and can involve multiple organ systems. Belumosudil is a ROCK2 selective inhibitor that works to reduce the immune system response causing the chronic graft versus host disease. Giving belumosudil may better treat patients with chronic graft versus host disease and prevent the n... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: Moffitt Cancer Center, Tampa, Florida +4 locations
Conditions: Chronic Graft Versus Host Disease
Register for Updates
A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)
NCT06211764
Recruiting
The purpose of this study is to compare disease free survival (DFS) in participants with recurrence of papillary-only high-risk non-muscle-invasive bladder cancer (HR-NMIBC) within 1 year of last dose of Bacillus Calmette-Guérin (BCG) therapy and who refused or are unfit for Radical Cystectomy (RC), receiving TAR-200 versus investigator's choice of single agent intravesical chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: Arkansas Urology, Little Rock, Arkansas +122 locations
Conditions: Non-Muscle Invasive Bladder Neoplasms
Register for Updates
An Open-label, Time-lagged, Dose-escalation Study to Evalaute the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa.
NCT06326476
Recruiting
This study is to investigate the efficacy of siplizumab in the treatment of Hidradenitis Suppurativa.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Hidradenitis Suppurativa
Register for Updates
A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma
NCT06550895
Recruiting
The purpose of this study is to define the safety of Ciltacabtagene Autoleucel (Cilta-cel) and Talquetamab in participants with high-risk multiple myeloma (MM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: University of Iowa Hospital and Clinics, Iowa City, Iowa +11 locations
Conditions: Multiple Myeloma
Register for Updates
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
NCT06662786
Recruiting
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, oxaliplatin (mFOLFOX6) or 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus cetuximab and mFOLFOX6 or FOLFIRI in adult participants with Kirsten rat sarcoma viral oncogene homolog (KRAS)/ Neuroblastoma R... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: St. Bernard's Medical Center, Jonesboro, Arkansas +196 locations
Conditions: Colorectal Neoplasms
Register for Updates
Measurement of Refractive Error in Pseudophakic Eyes Using an Autorefractor and a Wavefront Aberrometer
NCT06797856
Recruiting
Prospective, single-site, non-interventional, technician masked, randomized (instrument and examiner testing sequences), controlled, bilateral, parallel-group study.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
05/22/2025
Locations: SoCal Eye, Long Beach, California
Conditions: Measurement of Refractive Error
Register for Updates
Online Rotating Delivery of Perception/Production Enhanced Treatment for Rhotics
NCT06969521
Recruiting
The goal of this clinical trial is to determine whether perceptual training enhances speech perception and production outcomes in children with Residual Speech Sound Disorders (RSSD). The main questions it aims to answer are: Does pre-treatment speech production accuracy predict treatment response? Does perceptual acuity influence the effectiveness of perception-first versus production-first interventions? Researchers will compare TAU+Perception-first and TAU-first treatment conditions to see... Read More
Gender:
ALL
Ages:
Between 8 years and 17 years
Trial Updated:
05/22/2025
Locations: Montclair State University, Montclair, New Jersey
Conditions: Speech Sound Disorder
Register for Updates
Stress Hydrocortisone In Pediatric Septic Shock
NCT03401398
Recruiting
SHIPSS is a multi-institutional, prospective, controlled, randomized, double-blinded interventional trial that will examine the potential benefits and risks of adjunctive hydrocortisone prescribed for children with fluid and vasoactive-inotropic refractory septic shock. It is hypothesized that adjunctive hydrocortisone will significantly reduce the incidence of new and progressive organ dysfunction (primary outcome) and proportion of children with poor outcomes, defined as death or severely imp... Read More
Gender:
ALL
Ages:
Between 1 month and 17 years
Trial Updated:
05/22/2025
Locations: University of Arizona Medical Centre, Tucson, Arizona +50 locations
Conditions: Septic Shock
Register for Updates
Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Young Adults
NCT04249830
Recruiting
The purpose of the CliniMACS® TCRαβ-Biotin System and CliniMACS® CD19 is to improve the safety and efficacy of allogeneic HLA-partially matched related or unrelated donors HSCT when no matched donors are available, to treat malignant and nonmalignant disorders for which HSCT is the recommended best available therapy. Initially this device will be used in a single-center, open-label, single-arm, phase II clinical trial to evaluate the efficacy of haploidentical PBSC grafts depleted of TCRα/β+ and... Read More
Gender:
ALL
Ages:
Between 1 month and 60 years
Trial Updated:
05/22/2025
Locations: Lucile Packard Children's Hospital, Palo Alto, California
Conditions: Hematologic Diseases
Register for Updates
Ethicon Pelvic Mesh Post Market Clinical Follow-up Registry
NCT04829175
Recruiting
The objective of this post market, clinical registry is to evaluate the performance of the products of the TVT family of products or vaginal vault or uterine prolapse repair (with laparotomic or laparoscopic approach including robotic assisted) using either Gynemesh PS Mesh or Artisyn Mesh in women undergoing surgery for SUI and POP.
Gender:
FEMALE
Ages:
21 years and above
Trial Updated:
05/22/2025
Locations: Yale University, New Haven, Connecticut +10 locations
Conditions: Stress Urinary Incontinence, Pelvic Organ Prolapse
Register for Updates
A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis
NCT05083182
Recruiting
The purpose of this study is to evaluate the pharmacokinetics (PK), efficacy, safety and immunogenicity of ustekinumab and guselkumab in active juvenile psoriatic arthritis (jPsA).
Gender:
ALL
Ages:
Between 5 years and 17 years
Trial Updated:
05/22/2025
Locations: Childrens Hospital Los Angeles, Los Angeles, California +49 locations
Conditions: Arthritis, Juvenile
Register for Updates
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
NCT05421663
Recruiting
This is a Phase Ib multicenter, open-label study of JNJ-90014496, an autologous bi-specific chimeric antigen receptor (CAR) T-cell therapy, targeting both cluster of differentiation (CD) CD19 and CD20 for the treatment of adult participants with B-Cell non-Hodgkin lymphoma (B-NHL).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: City of Hope, Duarte, California +27 locations
Conditions: Lymphoma, Non-Hodgkin, Lymphoma, B-Cell
Register for Updates